NewsRoom Articles - Page 191 of 193

MondayFeb 24, 2020 12:37 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media

POAI subsidiary announces new media for growing ovarian tumors in lab Using new product, TumorGenesis partners have identified 25 cell types from ovarian cancers New media available as cell-culture market expected to reach $2.3 billion by 2024 Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, along with its subsidiary TumorGenesis Inc., has announced an innovative special media for growing ovarian tumors; the companies have also selected US Biological Corporation as a manufacturer and distributor of the groundbreaking media (http://nnw.fm/2bdtl). POAI anticipates the new formulations, which will be developed in a lab, will speed discovery of biomarkers…

WednesdayFeb 19, 2020 11:41 am

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Advances Precision Therapeutics by Learning Cancer Behavior, Improving Outcomes

Predictive Oncology subsidiary TumorGenesis developing faster, less costly and more accurate PDx cancer models that better mimic patient’s tumor TumorGenesis revolutionary technology will provide pharmaceuticals with quicker, more effective drug development while significantly improving patient outcomes POAI to begin sales of TumorGenesis’ innovative culture media in the first half of 2020 TumorGenesis, a flagship subsidiary of Predictive Oncology Inc. (NASDAQ: POAI), has made concrete steps in identifying and separating cancer-related biomarkers, which is likely to speed the development of new and effective therapeutics. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological…

MondayFeb 17, 2020 1:30 pm

Genprex Inc. (NASDAQ: GNPX) Starts Presentation at NobleCon16

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform. The company’s lead product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (“NSCLC”), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.genprex.com About BioMedWire BioMedWire…

FridayJan 24, 2020 12:44 pm

Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member, Audit Committee Chair

New board member, audit committee chair brings 35 years of accounting experience, mainly in management Prior worked as CFO, controller in several genomics, health companies POAI to leverage Prior’s new insights, guidance in the financial space Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, announced that Pam Prior, CPA, has been appointed to the company's Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee. Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller.…

FridayJan 17, 2020 12:42 pm

Predictive Oncology Inc. (NASDAQ: POAI), Leader in Precision Medicine, Committed to Playing Key Role in Decreasing Cancer Deaths

American Cancer Society annual report shows largest single-year drop in cancer deaths ever reported Doctors attribute precision medicine with playing significant role in decline POAI leading player in precision medicine, initiated groundbreaking Cancer Quest 2020 project A new American Cancer Society report bodes well for Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to help equip players in personalized medicine and drug discovery. American Cancer Society’s annual ‘Facts & Figures 2020’ report shows the largest single-year drop in cancer deaths ever reported (http://nnw.fm/twL1W). The 2.2% drop occurred from 2016 to 2017, the most recent year for…

MondayJan 13, 2020 12:11 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Disruptive Platform Overcoming Obstacles in Precision Medicine Industry

The global precision medicine market is estimated to reach $84.6 billion by 2024 Predictive Oncology is bringing cutting-edge technology to cancer research to develop highly customizable assessment methods that improve patient outcomes POAI leverages unique competitive advantage that stems from readily available access to historical data on tumor profiles and their drug responses Precision medicine, an approach that seeks to understand the genetic makeup of a patient’s tumor in order to customize a drug targeting the particular gene type for each patient, offers tremendous potential for the treatment of a number of diseases. Predictive Oncology Inc. (NASDAQ: POAI), a data…

FridayJan 10, 2020 1:09 pm

Predictive Oncology Inc. (NASDAQ: POAI) Working to Create World’s First Comprehensive, Actionable Multi-Omic Data Set for Ovarian Cancer

POAI plans to have first predictive model of ovarian cancer ready for initial commercialization in Q1 2020 First batch of 400 ovarian cancer subjects in initiative has been sequenced Groundbreaking AI-driven model of ovarian cancer will be capable of predicting tumor drug response, patient outcome Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has updated the commercialization of its pioneering CancerQuest 2020 initiative (http://nnw.fm/y6fnc). Based on the updated announcement, the company plans on having its first predictive model of ovarian cancer ready for initial commercialization in revenue-generating projects with Pharma…

TuesdaySep 24, 2019 9:00 am

Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

BioMedWire Editorial Coverage: Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.’s (NASDAQ: GNPX) (GNPX Profile) TUSC2 prevented tumor growth against triple-negative breast cancer. Eli Lilly and Company (NYSE: LLY) is focusing on those patients with the greatest need and, in the process, has developed a new breast-cancer treatment option. Roche Holding (OTCQX: RHHBY) is expanding the use of its biotech to both identify and treat patients with challenging breast cancers. AbbVie Inc. (NYSE: ABBV) has been rapidly increasing its research, targeting more than 15 different types of cancer.…

WednesdaySep 04, 2019 9:00 am

Gene Therapy Treatments Offer Hope for Cancer Patients

BioMedWire Editorial Coverage: Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is focused on using gene therapy to tackle lung cancer, developing new drugs that can be used alongside existing treatments. Pfizer Inc. (NYSE: PFE) has created a state-of-the-art research center focused on gene therapy treatments, which it uses for illnesses including cancer. Gilead Sciences Inc. (NASDAQ: GILD) is using biotechnology to tackle a range of challenging diseases, including HIV and hepatitis. Sarepta Therapeutics Inc. (NASDAQ: SRPT) is developing 20 different…

WednesdayAug 21, 2019 9:00 am

Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector

BioMedWire Editorial Coverage: Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) has completed key steps in its overall strategy to expand its clinical development programs and bring Oncoprex(TM) immunogene therapy, its lead drug candidate, to commercialization. Over the past five years, Amgen Inc. (NASDAQ: AMGN) has invested nearly $19 billion in R&D and, as a result, is now advancing a record number of clinical assets. Biogen Inc. (NASDAQ: BIIB) has added four new programs…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Advances Precision Therapeutics by Learning Cancer Behavior, Improving Outcomes

Genprex Inc. (NASDAQ: GNPX) Starts Presentation at NobleCon16

Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member, Audit Committee Chair

Predictive Oncology Inc. (NASDAQ: POAI), Leader in Precision Medicine, Committed to Playing Key Role in Decreasing Cancer Deaths

Predictive Oncology Inc.’s (NASDAQ: POAI) Disruptive Platform Overcoming Obstacles in Precision Medicine Industry

Predictive Oncology Inc. (NASDAQ: POAI) Working to Create World’s First Comprehensive, Actionable Multi-Omic Data Set for Ovarian Cancer

Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

Gene Therapy Treatments Offer Hope for Cancer Patients

Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search